Finance

Lists
IMCR:NASDAQ
Immunocore Holdings PLC - ADR
28,34 USD
+1,87%
(+0,52) 1D
28,34 USD
0,00% (0,00)
After hours
Closed: 14-окт., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMCR...
Open
27,60 USD
High
28,45 USD
Low
27,50 USD
Mkt. cap
1,48 млд
Avg. vol.
429,45 миң
Volume
0,00
52-wk high
40,71 USD
52-wk low
27,50 USD
EPS
-0,37 USD
Beta
0,81
Shares outstanding
51,50 млн
No. of employees
524
Open
27,60 USD
High
28,45 USD
Low
27,50 USD
Mkt. cap
1,48 млд
Avg. vol.
429,45 миң
Volume
0,00
52-wk high
40,71 USD
52-wk low
27,50 USD
EPS
-0,37 USD
Beta
0,81
Shares outstanding
51,50 млн
No. of employees
524
News stories
From web sources and news partners
Profile
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology. Wikipedia
About Immunocore Holdings PLC - ADR
CEOBahija Jallal
Employees524
Founded2008
Headquarters-
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to IMCR in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for IMCR in the last 3 months.
Highest
Current 28,34 USD
100,00 USD (+252,86%)
Average
62,83 USD (+121,70%)
Lowest
35,00 USD (+23,50%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Maintained
100,00 USD
+252,9%
09/21/2026
Jessica Fye
J.P. Morgan
Buy
Initiated
50,00 USD
+76,4%
08/21/2026
Sean Laaman
Morgan Stanley
Hold
Maintained
43,00 USD
+51,7%
08/07/2026
Rajan Sharma
Goldman Sachs
Buy
Maintained
74,00 USD
+161,1%
08/06/2026
Graig Suvannavejh
Mizuho Securities
Hold
Maintained
35,00 USD
+23,5%
08/07/2026
Gil Blum
Needham
Buy
Maintained
75,00 USD
+164,6%
08/06/2026
Unknown Analyst
Guggenheim
Hold
Maintained
-
-
05/06/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
60,00 USD
+111,7%
05/06/2026
Jeff Jones
Oppenheimer
Buy
Maintained
86,00 USD
+203,5%
04/20/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Maintained
60,00 USD
+111,7%
04/14/2026
Faisal Khurshid
Jefferies
Hold
Downgraded
33,00 USD
+16,4%
03/15/2026
Last report
2026-ж., 6-авг.
Fiscal period
Q2 2026
-0,02 USD / 0,02 USD
-195,65%miss
Revenue / Est. (USD)
115,93 млн / 110,92 млн
+4,51%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
103,69 млн
104,48 млн
106,68 млн
115,93 млн
Cost of goods sold
71,08 млн
81,52 млн
434,00 миң
75,03 млн
Cost of revenue
71,08 млн
81,52 млн
434,00 миң
75,03 млн
Research and development expenses
-
-
61,11 млн
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
39,78 млн
42,64 млн
37,85 млн
43,89 млн
Operating expense
39,78 млн
22,92 млн
98,96 млн
43,89 млн
Total operating expenses
110,86 млн
104,44 млн
99,40 млн
118,92 млн
Operating income
-7,17 млн
37,00 миң
7,28 млн
-3,00 млн
Other non operating income
5,06 млн
-15,22 млн
-
-
EBT including unusual items
304,00 миң
-15,79 млн
13,27 млн
-514,00 миң
EBT excluding unusual items
304,00 миң
-15,79 млн
11,50 млн
-3,58 млн
Income tax expense
481,00 миң
14,27 млн
301,00 миң
294,00 миң
Effective tax rate
158,22%
-90,33%
2,27%
-57,20%
Other operating expenses
-
-19,73 млн
-
-
Net income
-177,00 миң
-30,06 млн
12,97 млн
-808,00 миң
Net profit margin
-0,17%
-28,77%
12,16%
-0,70%
Earnings per share
-
-0,60
0,25
-0,02
Interest and investment income
4,12 млн
3,91 млн
3,42 млн
3,58 млн
Interest expense
-3,04 млн
-3,05 млн
-3,05 млн
-3,06 млн
Net interest expenses
1,08 млн
853,00 миң
367,00 миң
520,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-6,37 млн
871,00 миң
8,23 млн
-1,97 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору